Coronavirus disease 2019 (COVID-19) started as an epidemic in Wuhan China and rapidly became a global pandemic attributed to a novel coronavirus—severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The virus was rapidly sequenced, enabling diagnostic tools relevant for use in clinical trial and providing targets for vaccines and therapeutics. As new variants continue to emerge, virus sequencing will play critical and ongoing role in drug and vaccine development.
In this webinar, we will:
- Establish the medical backdrop for COVID-19 virus sequencing in drug development
- Connect insights from population surveillance to potential solutions for drug developers
- Describe the biological relevance of sequencing in drug development
- Outline approaches to COVID-19 virus sequencing, including the application of both targeted and whole genome sequencing to drug development